IDiyas

For the Inventor, By the Inventor

Illkirch Graffenstaden, France

Transgene S.a.


USPTO Granted Patents = 158



Trademarks = 4

Forward Citations = 1,252

Loading Chart...
Loading Chart...

156 inventors (with patents filed for the assignee):

goldMedal Nathalie Silvestre (18 out of 20 patents)

silverMedal Philippe Erbs (17 out of 17 patents)

bronzeMedal Majid Mehtali (16 out of 32 patents)

4.  Marie-Paule Kieny (15 out of 18 patents)

5.  Claude Sene (12 out of 12 patents)

6.  Jean-Baptiste Marchand (10 out of 13 patents)

7.  Jean-Marc Balloul (10 out of 13 patents)

8.  Michel Geist (9 out of 9 patents)

9.  Yves Cordier (8 out of 8 patents)

10.  Jean-Pierre Lecocq (8 out of 10 patents)

11.  Richard Lathe (8 out of 15 patents)

12.  Perrine Martin (7 out of 7 patents)

13.  Christine Thioudellet (7 out of 8 patents)

14.  Marina Kapfer (7 out of 7 patents)

15.  Anne Fournillier (7 out of 9 patents)


Core Competencies:
Oncolytic Virus
Immune Checkpoint Modulators
HBV Infection
Mycobacterial Antigens
Poxviral Vectors
Dendritic Cells
Cancer Biomarkers
Avian Cell Lines
HCV Therapeutics
Signaling Peptides
Polypeptide Activity
Antitumoral Treatments

158 patents:

1. 11779619 - Oncolytic virus for expression of immune checkpoint modulators (2023-10-10),
2. 10857226 - Composition for treating HBV infection (2020-12-08),
3. 10765731 - Fusion of heterooligomeric mycobacterial antigens (2020-09-08),
4. 10765710 - Combination of oncolytic virus with immune checkpoint modulators (2020-09-08),
5. 10662414 - Methods for treating or preventing HBV infection or HBV related diseases (2020-05-26),
6. 10555981 - Oncolytic virus for expression of immune checkpoint modulators (2020-02-11),
7. 10517943 - Stable liquid vaccinia virus formulations (2019-12-31),
8. 10357555 - Mycobacterial antigen vaccine (2019-07-23),
9. 10190105 - HBV polymerase mutants (2019-01-29),
10. 10111947 - Virus-containing formulation and use thereof (2018-10-30),
11. 10076570 - Composition for treating HBV infection (2018-09-18),
12. 9982055 - Antibody against the CSF-1R (2018-05-29),
13. 9884080 - Poxviral oncolytic vectors (2018-02-06),
14. 9687515 - Poxviral oncolytic vectors (2017-06-27),
15. 9676859 - In vitro generation of dendritic cells by exposure to an anti-CSF1-R antibody (2017-06-13),
Transgene S.A. is a French biotechnology company that focuses on developing innovative immunotherapies for the treatment of cancer and infectious diseases. With a strong expertise in viral vector engineering, the company aims to deliver novel products that harness the power of the immune system to fight diseases. Transgene's pipeline includes both clinical-stage candidates and preclinical programs, targeting a range of cancer types. The company is committed to improving patient outcomes through its cutting-edge research and partnerships with global pharmaceutical companies.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

...
158 Patents

#1 in Illkirch Graffenstaden

#170 in France

#5,068 in the World

...
Illkirch Graffenstaden, France

Transgene S.a.

Forward Citations = 1,252

156 inventors:

goldMedal Nathalie Silvestre (18 out of 20 patents)

silverMedal Philippe Erbs (17 out of 17 patents)

bronzeMedal Majid Mehtali (16 out of 32 patents)

4.  Marie-Paule Kieny (15 out of 18 patents)

5.  Claude Sene (12 out of 12 patents)

Please report any incorrect information to support@idiyas.com
Loading…